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Trisomy 15mosaicism (mosT15) has been described in fetuses and
live-born infants [Christian et al., 1996; Redaelli et al., 2005], with
most cases involving confined placental mosaicism (CPM) and
meiotic non-disjunction (ND) [EUCROMIC, 1999]. Poor preg-
nancy outcome prognosis is associated with the presence of aneu-
ploid cells, and there is also a risk of uniparental disomy 15
(UPD15) due to correction of the trisomic state to a disomic
constitution. Trisomy or monosomy rescue, gamete complemen-
tation and postfertilization error are the main mechanisms leading
to UPD and may cause heterodisomy (heteroUPD), isodisomy
(isoUPD) or both, depending on the number of meiotic recombi-
nations. The result of maternal (matUPD) and paternal (patUPD)
UPD15 is Prader–Willi and Angelman syndrome, respectively, due
to imprinting of chromosome region 15q11–15q13. UPDdetection
can only be achieved using molecular methodologies, such as
methylation-specific assays (MSA) [Kotzot, 2008] and, more re-
cently, genome-wide single nucleotide polymorphism (SNP)
arrays [Conlin et al., 2010; Schroeder et al., 2013]. MSA allow
for methylation pattern analysis of the chromosome regions of
interest and SNP-arrays may provide information about copy
number as well as UPD, in cases of isoUPD or isodisomy secondary
to recombination. HeteroUPD may also be diagnosed by SNP-
arrays if parental and proband DNAs are analyzed in a trio [Conlin
et al., 2010; Schroeder et al., 2013]. However, not all molecular
methods are equally informative and when a mosaicism is present,
especially in a prenatal setting, parent-of-origin analysis as well as
karyotype–phenotype correlations become quite challenging. Here
we report on a fetus with a CVS diagnosed mosT15 with different
degrees of mosaicism found in different tissues and briefly discuss
the challenges of prenatal diagnosis of UPD15.
The patient was a 38-year-old, primigravid woman who under-
went an in vitro fertilization procedure (IVF) due to infertility after
a bilateral salpingectomy. First trimester combined screening at
12 weeks was positive due to increased fetal nuchal translucency
(5.0mm, 95th centile). After counseling regarding diagnostic
options, fetal karyotyping was offered and the couple opted for
CVS which was performed at 12 weeks of gestation. Cleaned villi
were (i) finely diced and two MLPA experiments performed (after2015 Wiley Periodicals, Inc.DNA extraction by a salting-out in house procedure); and (ii)
digested enzymatically with trypsin (0.5% 20min., 37˚C, 95% RH)
and collagenase type V (300UI/ml 2 hr, 37˚C, 95%RH). An aliquot
of the latter was then separated for aMLPA experiment (after DNA
extraction using the IntrageneMatrix kit, CA) and the remnantwas
cultured for karyotype analysis using standard methods. MLPA
results were consistent with the absence of aneuploidy for chro-
mosomes 13, 18, and 21 in a female fetus, and cytogenetic analysis
on long-term CVS cultures revealed the presence of trisomy 15 in
16 of 22 cells examined. In order to evaluate the possibility of a
trisomy 15 CPM, amniocentesis was offered and performed at
18weeks of gestation. Chromosome analysis of amniocytes showed
a supernumerary chromosome 15 in 14 of 50metaphases analyzed,
thus indicating the presence of a true fetal mosT15. Ultrasound
examination at 21þ 1 gestational weeks revealed a small ventricu-
lar septal defect (VSD), nuchal and pre-nasal edema, hypoplastic1
2 AMERICAN JOURNAL OF MEDICAL GENETICS PART Anasal bone (<5th centile) and clinodactily of the left hand. Parental
karyotypes were normal.
Methylation-specific PCR (MS-PCR) was performed on bisul-
fate-treated genomic DNA using primers specific for methylated
sites within the SNRPN exon 1/promoter region. The sodium
bisulfite treatment was done using the Imprint 1 DNA Modifica-
tion Kit (Sigma-Aldrich, Saint Louis, MI) according to manufac-
turer’s instructions. MS-PCR was performed using one common
primer that anneals to both alleles and one specific primer each for
the methylated (maternal) and unmethylated (paternal) allele as
previously described [Zeschnigk et al., 1997]. Amplification prod-
ucts were electrophoresed on an agarose gel along with appropriate
positive and negative controls. MS-PCR on the CVS revealed two
bands, one for the maternal allele and one for the paternal, the
former a little more intense than the latter. Given the presence of
the trisomy mosaicism, parent of origin conclusions were not
possible. MS-PCR on the AF sample showed the presence of
two bands, one for the maternal allele and one for the paternal,
but with no discernible difference between them (Fig. 1). After
counseling the couple opted for termination of pregnancy which
was performed at 22 weeks of gestation. A fetal skin (FS) biopsy was
explanted and cultured according to the standard tissue explant
technique modified from Verma and Babu [1995] and cytogenetic
analysis revealed a low level mosaicism (2%) for trisomy 15. MS-
PCR on the FS sample showed similar results to the ones of the AF
sample (Fig. 1). Anatomopathological investigations showed a
female fetus with 480 g, 19 cm head circumference and 18.4 cm
crown-rump length. External examination revealed hypertelorism,
broad flat nasal bridge, micrognathia, low implantation and pos-
terior angulation of the ears and right club foot. The heart
examination showed a perimembranous VSD. The placenta was
hypoplastic, there was villi edema and a single umbilical artery was
present.
SNP arraywas performedusing genomicDNAand theCytoScan
HD array (Affymetrix, Santa Clara, CA) was utilized for this
analysis and includes more than 2.69 million probes, of which
1.9million are non-polymorphic copy number probes and 740,000
are SNP probes that genotype with over 99% accuracy. GenomicFIG. 1. MS-PCR analysis from chorionic villi (VCB), amniotic fluid
(AF) and fetal skin (FSB) samples and controls. PWS—PWS
patient; AS—AS patient; CN—normal control; M—100–1000 bp
ladder; Ø—PCR control; MAT—maternal PCR product; PAT—
paternal PCR product.coordinates are based upon genome build ucsc hg19. Hybridiza-
tion, data extraction and analysis were done as per manufacturer’s
protocols. The Affymetrix Chromosome Analysis Suite 2.1.0.16
with NetAffx na33 and Genotype Console v4.0 softwares were used
for data analysis and review. SNP array revealed mosaic parental
heterodisomy for the entire chromosome 15 (Fig. 2). The mosaic
was estimated to be at the level of approximately 29% and 26% on
the CVS and AF samples repectively and not detected on the FS
sample. No monosomy or gains/losses were suggested by the SNP
array. Trio analysis was performed using UPDtool as described by
Schroeder et al. [2013]. SNP array analysis was performed on CVS,
AF, and FS and on parental blood samples.
To our knowledge, our case shows the fetal mosT15 with the
highest level of trisomy 15 on CVS cells, where the mosaicism was
not confined to the placenta (as confirmed both on AF and FS)
described thus far. This may account for the difficulties in assessing
the UPD status as well as the mechanism underlying the mosaic
formation. MS-PCR showed biparental contribution and no con-
clusive indication about UPD although a higher maternal content
was suspected. SNP array on the other hand, allowed for the
exclusion of copy-number gains/losses, and the absence of large
blocks of homozigosity on chromosome 15 suggested a parental
heterodisomy, which is consistent with a parental meiosis I ND.
Malsegregation inmeiosis II,monosomy rescue and somatic events
were excluded since they would have resulted in isodisomy 15. Trio
analysis revealed a maternal/paternal ratio of 60% or 40%, which
also suggests a higher maternal contribution and therefore a
probable matUD15 (maternal inheritance shown in Table I).
We also observed divergent results between karyotype and SNP-
array analyses regarding trisomic cell levels on CVS (73% and 29%,
respectively). This type of divergence has been reported before for
peripheral blood samples [Conlin et al., 2010] and, in this case,may
be due to heterogeneous cell distribution in the placenta and/or cell
culture selection, since the villi tissue used for SNP-array was
mainly cytotrophoblastic in origin and the cytogenetic analysis
was performed on amixture of cytotrophoblast- andmesenchyme-
originated cultured cells. Nevertheless the confirmation of placen-
tal mosaicism on both CVS cell populations also indicates trisomy
rescue involvement in themosaic formation.We assume, therefore,
that an initial meiosis I maternal ND occurred, followed by a
trisomic conception and a subsequent postzygotic trisomy rescue
with the resulting mosaicism and maternal heterodisomy. The
advanced maternal age also argues in favor of a maternal ND,
since it is a well known risk factor in the etiology of trisomy 15, as
well as in other aneuploidies [Ginsburg et al., 2000]. The fact that
the pregnancy resulted from an IVF procedure should also be taken
into account, as a high frequency of ND has been estimated in IVF
patients of advanced reproductive age [Robinson et al., 1999].
UPD investigation is difficult when mosaicism is present, due
to the contribution of genetically different cell lines, even when
trio analysis is performed [Schroeder et al., 2013]. In our case, the
molecular results presented a dilemma in terms of interpretation
and counseling. Even though they were not conclusive regarding
parent-of-origin, the fetal phenotype described is consistent
with previous reports of mosT15, that include congenital
heart disease (e.g., VSD, mitral atresia), craniofacial (e.g., hyper-
telorism, broad flat nasal bridge, micrognathia) and skeletal
FIG. 2. SNP-array analysis results on the fetal samples showing mosaic gain on CVS and AF samples and no detectable mosaic on the fetal
skin sample.
SILVA ET AL. 3anomalies (e.g., abnormal rib number, clenching/overlapping of
the fingers) [Christian et al., 1996; Olander et al., 2000; Redaelli
et al., 2005]. PWS was confirmed, through molecular techniques
by other authors either due to trisomy 15/matUPD15 mosaicism
or non-mosaic matUPD15 and complete maternal heteroUPD15
has been found in around 21–29% of PWS patients [Tucker et al.,
2012] with morphological features consistent with the ones we
describe. Nevertheless, given that a confirmed mosT15 was
present, with such a high level of abnormal cells on CVS, it isTABLE I. Absence of Paternal Co
Probe Set Name Chromosomal Position Father’s g
S-3BDEI 26133343 AA
S-3YWBB 26406413 AA
S-4BUYR 46850579 AA
S-3OMPW 56172652 BB
S-3DOIM 59941622 BB
S-4EYSM 62044136 BB
S-3WATJ 70004352 AA
S-4MOCI 91676168 AA
S-3VYIN 92874777 BB
S-4PMET 100366944 BB
Shown are examples of informative SNP genotypes from trio analysis using the CytoScan HD SNP mi
genomik-software.html). SNP alleles are assigned “A“ or “B“ at each loci by the Affymetrix Chromosom
proband and mother at the examined loci are consistent with heterodisomy.highly likely that the trisomy has had a more negative effect on
the phenotype than the presence of UPD itself as previously
proposed [Olander et al., 2000]. Even though the fetus we
describe was referred at an early gestational age when only
increased nuchal translucency was observed, other fetal alter-
ations were found thereafter (both on ultrasound and postmor-
tem), confirming the expected more severe phenotype due to the
presence of trisomy 15. The presence of single umbilical artery as
well as of placental abnormalities might lead us to expect IUGR,ntribution to Chromosome 15
enotype Proband’s genotype Mother’s genotype
BB BB
BB AB
BB BB
AA AA
AA AA
AA AA
BB AB
BB BB
AA AB
AA AB
croarray (Affymetrix Inc., Santa Clara, CA) and UPDtool (http://www.uni-tuebingen.de/uni/thk/de/f-
e Analysis software (ChAS; Affymetrix Inc., Santa Clara, CA). The identical genotypes between the
4 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aas in previous reports [Christian et al., 1996; Redaelli et al., 2005].
However we did not observed IUGR, possibly due to heteroge-
neous distribution of the trisomic cell line in the placental tissue
that would not render enough severity of transport/metabolic
dysfunction to compromise fetal growth.
Differentiating between a mitotic and a meiotic origin for
trisomy 15 is, as for other trisomies, important for proper
counseling and determining recurrence risks, because trisomy
as a result of meiotic ND is associated with a higher risk of
recurrence [Christian et al., 1996]. Assessing the mechanism
involved is not always a straightforward endeavour in prenatal
diagnosis of mosT15 since not all methodologies are equally
informative and phenotype information is limited (e.g., there is
no possibility of neurological development evaluation). Even in a
time when highly accurate and high-throughput DNA-based
testing is so widely available, the limitations of those tests should
always be taken into consideration, especially before establishing
genotype–phenotype correlations.REFERENCES
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